{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:14:22Z","timestamp":1793049262899,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000296","name":"British Skin Foundation","doi-asserted-by":"publisher","award":["006\/R\/22"],"award-info":[{"award-number":["006\/R\/22"]}],"id":[{"id":"10.13039\/501100000296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007287","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","award":["24-0087"],"award-info":[{"award-number":["24-0087"]}],"id":[{"id":"10.13039\/501100007287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/L023091\/1; MR\/V049445\/1); MR\/R015643\/1"],"award-info":[{"award-number":["MR\/L023091\/1; MR\/V049445\/1); MR\/R015643\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["IES\\R2\\222084"],"award-info":[{"award-number":["IES\\R2\\222084"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRUK City of London Centre Award","award":["C7893\/A29290"],"award-info":[{"award-number":["C7893\/A29290"]}]},{"name":"Guy\u2019s and St Thomas\u2019s Foundation Trust Charity Melanoma Special Fund","award":["573"],"award-info":[{"award-number":["573"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>B cells are increasingly recognized regulators of antitumor immunity in melanoma, yet their differentiation states, lineage dynamics, spatial organization and integration within the immune microenvironment, and how these are influenced with immunotherapy remain incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted deep profiling of tumor-resident B cell differentiation and evolutionary features in the melanoma tumor microenvironment using bulk, single-cell and spatial transcriptomic analyses, long-read antibody sequencing and mass cytometry (Cytometry by Time-Of-Flight, CyTOF). We characterized B cell differentiation trajectories, class-switching patterns, antibody isotype usage, signaling pathways, spatial niches against clinicopathological features and immune cell communication, before and after checkpoint blockade and in clinically defined responders and non-responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Melanoma-infiltrating B cells were enriched across primary and metastatic lesions, were preferentially associated with immune-rich tumors and correlated with T and natural killer (NK) cell densities. Long-read immunoglobulin sequencing demonstrated recurrent class switch recombination (CSR) trajectories with predominant IgG and IgA isotype usage, confirmed by bulk transcriptomic analyses. Across independent single-cell and bulk transcriptomic datasets we identified conserved class-switching, B cell receptor (BCR) activation, and pseudotime analyses showed differentiation trajectories progressing from na\u00efve and memory states toward interferon (IFN)-driven terminal differentiation trajectories that persisted before and after immunotherapy. CyTOF analyses independently confirmed proliferative, germinal center (GC)-like, memory and class-switched B cell subsets, suggesting conserved inflammatory differentiation endpoints. Spatial transcriptomic deconvolution identified IFN-rich B cells within tertiary lymphoid structures (TLS). Following immunotherapy, B cells retained class-switched trajectories, displayed enriched GC-associated profiles, enhanced crosstalk with T cells and Dendritic Cells (DCs) and preserved or induced IFN-rich IgM\u2009+\u2009\/IgD\u2009+\u2009or IgG4\u2009+\u2009phenotypes, suggesting persistence or emergence of non-class switched and atypical class-switched isotype profiles. Transcriptomic analyses of B cells pointed to upregulated antigen-driven stimulation and BCR signaling, whereas in non-responders displayed IFN-rich B cells, IFN-associated genes, and IFN-pathway enrichment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Melanoma-infiltrating B cells follow class-switched differentiation trajectories culminating in IFN signaling, atypical antibody expressing states that persist or emerge after immunotherapy, aligning dynamic B cell evolution and atypical lineage traits with immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03797-1","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:27:07Z","timestamp":1786058827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor-infiltrating B cells evolve towards interferon-rich trajectories aligned with immunotherapy in melanoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Katie","family":"Stoker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Laddach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Crescioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Maiques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitesh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinethri","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L. C.","family":"Geh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D","family":"MacKenzie Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawys","family":"Lloyd-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Fraternali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kipling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah K.","family":"Dunn-Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Tull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Tsoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-7810","authenticated-orcid":false,"given":"Sophia N.","family":"Karagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"3797_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.498703\/","volume":"11","author":"K Akita","year":"2021","unstructured":"Akita K, et al. Interferon \u03b1 Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. Front Immunol. 2021;11:498703. https:\/\/doi.org\/10.3389\/FIMMU.2020.498703\/.","journal-title":"Front Immunol"},{"issue":"13","key":"3797_CR2","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.cell.2022.04.028","volume":"185","author":"N Alphonse","year":"2022","unstructured":"Alphonse N, et al. A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling. Cell. 2022;185(13):2354-2369.e17. https:\/\/doi.org\/10.1016\/j.cell.2022.04.028.","journal-title":"Cell"},{"issue":"1","key":"3797_CR3","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"3797_CR4","doi-asserted-by":"crossref","unstructured":"Bao X, et al. \u2018Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy\u2019. Front Immunol. 2024;15:1413067. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/.","DOI":"10.3389\/fimmu.2024.1413067"},{"key":"3797_CR5","doi-asserted-by":"publisher","unstructured":"Bodzioch M. et al. Evidence for potential functionality of nuclearly-encoded humanin isoforms. Genomics. 2009;94(4):247\u201356. https:\/\/doi.org\/10.1016\/j.ygeno.2009.05.006.","DOI":"10.1016\/j.ygeno.2009.05.006"},{"issue":"10","key":"3797_CR6","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nbt.3979","volume":"35","author":"DA Bolotin","year":"2017","unstructured":"Bolotin DA, et al. Antigen receptor repertoire profiling from RNA-seq data. Nat Biotechnol. 2017;35(10):908\u201311. https:\/\/doi.org\/10.1038\/nbt.3979.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3797_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/modpathol.2016.28","volume":"29","author":"FM Bosisio","year":"2016","unstructured":"Bosisio FM, Wilmott JS, Volders N, Mercier M, Wouters J, Stas M, et al. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol. 2016;29(4):347\u201358. https:\/\/doi.org\/10.1038\/modpathol.2016.28.","journal-title":"Mod Pathol"},{"key":"3797_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041262","author":"O Briem","year":"2023","unstructured":"Briem O, et al. CD169+ macrophages in primary breast tumors associate with tertiary lymphoid structures, Tregs and a worse prognosis for patients with advanced breast cancer. Cancers (Basel). 2023;15(4):1262. https:\/\/doi.org\/10.3390\/cancers15041262.","journal-title":"Cancers (Basel)"},{"key":"3797_CR9","doi-asserted-by":"publisher","unstructured":"Cable DM, et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nature Biotechnol. 2021;40(4):517\u201326. https:\/\/doi.org\/10.1038\/s41587-021-00830-w.","DOI":"10.1038\/s41587-021-00830-w"},{"key":"3797_CR10","doi-asserted-by":"publisher","unstructured":"Cabrita R, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1914-8.","DOI":"10.1038\/s41586-019-1914-8"},{"key":"3797_CR11","doi-asserted-by":"crossref","unstructured":"Colbeck EJ, et al. Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease? Front Immunol. 2017;8:1830. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/.","DOI":"10.3389\/fimmu.2017.01830"},{"issue":"1","key":"3797_CR12","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1038\/s41467-023-39042-y","volume":"14","author":"S Crescioli","year":"2023","unstructured":"Crescioli S, et al. B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma. Nat Commun. 2023;14(1):3378. https:\/\/doi.org\/10.1038\/s41467-023-39042-y.","journal-title":"Nat Commun"},{"key":"3797_CR13","doi-asserted-by":"publisher","unstructured":"Dimitrov D, et al. Comparison of methods and resources for cell-cell communication inference from single-cell RNA-Seq data. Nat Commun 2022;13(1):1\u201313. https:\/\/doi.org\/10.1038\/s41467-022-30755-0.","DOI":"10.1038\/s41467-022-30755-0"},{"issue":"13","key":"3797_CR14","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100926","volume":"38","author":"D Fisch","year":"2019","unstructured":"Fisch D, et al. Human GBP1 is a microbe\u2010specific gatekeeper of macrophage apoptosis and pyroptosis. EMBO J. 2019;38(13):e100926. https:\/\/doi.org\/10.15252\/embj.2018100926.","journal-title":"EMBO J"},{"issue":"12","key":"3797_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717\u201334. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3797_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister C, Satija R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 2019;20(1):296. https:\/\/doi.org\/10.1186\/s13059-019-1874-1.","journal-title":"Genome Biol"},{"issue":"16","key":"3797_CR17","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/0008-5472.CAN-20-3773","volume":"81","author":"RJ Harris","year":"2021","unstructured":"Harris RJ, et al. Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. Cancer Res. 2021;81(16):4290\u2013304. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3773.","journal-title":"Cancer Res"},{"key":"3797_CR18","doi-asserted-by":"publisher","unstructured":"Hao Y, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42(2):293\u2013304. https:\/\/doi.org\/10.1038\/S41587-023-01767-y.","DOI":"10.1038\/S41587-023-01767-y"},{"issue":"7791","key":"3797_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549\u201355. https:\/\/doi.org\/10.1038\/s41586-019-1922-8.","journal-title":"Nature."},{"key":"3797_CR20","doi-asserted-by":"publisher","unstructured":"Jenks SA, et al. Distinct effector B-cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in Systemic Lupus Erythematosus. Immunity. 2018;49(4):725. https:\/\/doi.org\/10.1016\/J.IMMUNI.2018.08.015","DOI":"10.1016\/J.IMMUNI.2018.08.015"},{"key":"3797_CR21","doi-asserted-by":"publisher","unstructured":"Jimenez-Sanchez A, Cast O, Miller ML. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 2019;79(24):6238\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3560.","DOI":"10.1158\/0008-5472.CAN-18-3560"},{"issue":"7","key":"3797_CR22","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.4049\/jimmunol.1600281","volume":"198","author":"S Kang","year":"2017","unstructured":"Kang S, et al. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198(7):2602\u201311. https:\/\/doi.org\/10.4049\/jimmunol.1600281.","journal-title":"J Immunol"},{"issue":"4","key":"3797_CR23","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1172\/JCI65579","volume":"123","author":"P Karagiannis","year":"2013","unstructured":"Karagiannis P, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest. 2013;123(4):1457\u201374. https:\/\/doi.org\/10.1172\/JCI65579.","journal-title":"J Clin Invest"},{"key":"3797_CR24","doi-asserted-by":"publisher","unstructured":"Karagiannis P, et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015;4(11). https:\/\/doi.org\/10.1080\/2162402X.2015.1032492.","DOI":"10.1080\/2162402X.2015.1032492"},{"issue":"56","key":"3797_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe6291","volume":"6","author":"HW King","year":"2021","unstructured":"King HW, et al. Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics. Sci Immunol. 2021;6(56):eabe6291. https:\/\/doi.org\/10.1126\/sciimmunol.abe6291.","journal-title":"Sci Immunol"},{"key":"3797_CR26","doi-asserted-by":"publisher","unstructured":"Kolberg L, et al. g:Profiler\u2014interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51(W1):W207\u2013W212. https:\/\/doi.org\/10.1093\/nar\/gkad347.","DOI":"10.1093\/nar\/gkad347"},{"issue":"D1","key":"3797_CR27","doi-asserted-by":"publisher","first-page":"D413","DOI":"10.1093\/nar\/gku1056","volume":"43","author":"M-P Lefranc","year":"2015","unstructured":"Lefranc M-P, et al. IMGT\u00ae, the international ImMunoGeneTics information system\u00ae 25 years on. Nucleic Acids Res. 2015;43(D1):D413\u201322. https:\/\/doi.org\/10.1093\/nar\/gku1056.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3797_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","volume":"176","author":"H Li","year":"2019","unstructured":"Li H, et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2019;176(4):775-789.e18. https:\/\/doi.org\/10.1016\/j.cell.2018.11.043.","journal-title":"Cell"},{"issue":"1","key":"3797_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56299-7","volume":"16","author":"O Maiques","year":"2025","unstructured":"Maiques O, et al. Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis. Nat Commun. 2025;16(1):1394. https:\/\/doi.org\/10.1038\/s41467-025-56299-7.","journal-title":"Nat Commun"},{"key":"3797_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110766","author":"N Meednu","year":"2022","unstructured":"Meednu N, et al. Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression. Cell Rep. 2022;39:110766. https:\/\/doi.org\/10.1016\/j.celrep.2022.110766.","journal-title":"Cell Rep"},{"key":"3797_CR31","doi-asserted-by":"publisher","unstructured":"Mootha VK. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267\u201373. https:\/\/doi.org\/10.1038\/ng1180.","DOI":"10.1038\/ng1180"},{"key":"3797_CR32","doi-asserted-by":"publisher","unstructured":"Nemazee D, Weigert M. Revising B Cell Receptors. J Exp Med. 2000;191(11):1813. https:\/\/doi.org\/10.1084\/JEM.191.11.1813.","DOI":"10.1084\/JEM.191.11.1813"},{"issue":"4","key":"3797_CR33","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998-1013.e20. https:\/\/doi.org\/10.1016\/j.cell.2018.10.038.","journal-title":"Cell"},{"key":"3797_CR34","doi-asserted-by":"publisher","unstructured":"Saul L. et al. IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep. 2016;6(1):29736. https:\/\/doi.org\/10.1038\/srep29736.","DOI":"10.1038\/srep29736"},{"key":"3797_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-immunol-041015-055649","volume":"34","author":"O Schulz","year":"2016","unstructured":"Schulz O, et al. Chemokines and chemokine receptors in lymphoid tissue dynamics. Annu Rev Immunol. 2016;34:203\u201342. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055649.","journal-title":"Annu Rev Immunol"},{"key":"3797_CR36","doi-asserted-by":"publisher","first-page":"807104","DOI":"10.3389\/FIMMU.2022.807104","volume":"13","author":"A Stewart","year":"2022","unstructured":"Stewart A, et al. Pandemic, epidemic, endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-CoV-2, Ebola and respiratory syncytial virus. Front Immunol. 2022;13:807104\u2013807104. https:\/\/doi.org\/10.3389\/FIMMU.2022.807104.","journal-title":"Front Immunol"},{"key":"3797_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4772-0","author":"K Street","year":"2018","unstructured":"Street K, et al. Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. BMC Genomics. 2018;19:477. https:\/\/doi.org\/10.1186\/s12864-018-4772-0.","journal-title":"BMC Genomics"},{"issue":"1","key":"3797_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00891-z","volume":"9","author":"X Su","year":"2025","unstructured":"Su X, et al. Tertiary lymphoid structures associated with improved survival and enhanced antitumor immunity in acral melanoma. NPJ Precis Oncol. 2025;9(1):103. https:\/\/doi.org\/10.1038\/s41698-025-00891-z.","journal-title":"NPJ Precis Oncol"},{"key":"3797_CR39","doi-asserted-by":"publisher","unstructured":"Subramanian A, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","DOI":"10.1073\/pnas.0506580102"},{"key":"3797_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103438","author":"HJ van Dooren","year":"2025","unstructured":"van Dooren HJ, et al. Interferon signatures fuel B cell hyperactivity and plasmablast expansion in systemic lupus erythematosus. J Autoimmun. 2025;154:103438. https:\/\/doi.org\/10.1016\/j.jaut.2025.103438.","journal-title":"J Autoimmun"},{"key":"3797_CR41","doi-asserted-by":"publisher","unstructured":"Velounias RL, Tull TJ. Human B-cell subset identification and changes in inflammatory diseases. Clin Exp Immunol. Oxford University Press. 2022;210(3):201\u201316. https:\/\/doi.org\/10.1093\/cei\/uxac104.","DOI":"10.1093\/cei\/uxac104"},{"issue":"36","key":"3797_CR42","doi-asserted-by":"publisher","first-page":"38538","DOI":"10.18632\/oncotarget.6041","volume":"6","author":"E Verjans","year":"2015","unstructured":"Verjans E, et al. The cAMP response element modulator (CREM) regulates TH2 mediated inflammation. Oncotarget. 2015;6(36):38538\u201351. https:\/\/doi.org\/10.18632\/oncotarget.6041.","journal-title":"Oncotarget"},{"issue":"5","key":"3797_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2025-011682","volume":"13","author":"ZN Willsmore","year":"2025","unstructured":"Willsmore ZN, et al. Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanoma. J Immunother Cancer. 2025;13(5):e011682. https:\/\/doi.org\/10.1136\/JITC-2025-011682.","journal-title":"J Immunother Cancer"},{"key":"3797_CR44","doi-asserted-by":"publisher","unstructured":"Yuuki H, et al. B cell receptor repertoire abnormalities in autoimmune disease. Front Immunol. 2024;15:1326823. https:\/\/doi.org\/10.3389\/fimmu.2024.1326823.","DOI":"10.3389\/fimmu.2024.1326823"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03797-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03797-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:25:40Z","timestamp":1787631940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03797-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03797-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Research & Development Office of Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London (REC reference: 08\/H0804\/139 was approved by London Bridge NRES committee; REC reference: 16\/LO\/0366 (MISST, melanoma) was approved by London-Central NRES Committee). All methods\/study procedures were carried out in accordance with the Declaration of Helsinki. All participants were informed about the purpose of the study, assured of confidentiality, and provided written consent prior to participation. Participation was voluntary, and respondents could withdraw at any time without consequence.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.N.K. is academic founder and shareholder of Epsilogen Ltd. and declares patents on antibody technologies for cancer. J.C. was previously employed through a fund provided by Epsilogen Ltd. O.M. receives consulting services for Panakeia Technologies, UK. Y.W. consults for E15 VC and Prokarium. T.J.T. consults for Argenx and Immunovant. All other authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"186"}}